Piper Jaffray Companies upgraded shares of Bausch Health Companies (NYSE:BHC) from an underweight rating to a neutral rating in a research note released on Thursday, September 13th, Marketbeat Ratings reports. The firm currently has $19.00 price target on the stock, up from their prior price target of $16.00.
A number of other analysts have also recently commented on BHC. JPMorgan Chase & Co. upped their price target on shares of Bausch Health Companies to $18.00 and gave the company an underweight rating in a research report on Wednesday, August 8th. Cantor Fitzgerald reaffirmed a buy rating and set a $32.00 price target on shares of Bausch Health Companies in a research report on Tuesday, August 7th. Mizuho reaffirmed a buy rating and set a $31.00 price target on shares of Bausch Health Companies in a research report on Tuesday, August 7th. Royal Bank of Canada upped their price target on shares of Bausch Health Companies from $25.00 to $26.00 and gave the company a hold rating in a research report on Wednesday, August 8th. Finally, Wells Fargo & Co reissued a sell rating on shares of Bausch Health Companies in a research report on Monday, August 6th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $26.89.
Shares of Bausch Health Companies stock traded up $0.17 during trading on Thursday, hitting $26.49. The company’s stock had a trading volume of 5,232,200 shares, compared to its average volume of 8,377,615. The company has a quick ratio of 0.89, a current ratio of 1.14 and a debt-to-equity ratio of 6.99. Bausch Health Companies has a 52 week low of $10.94 and a 52 week high of $28.45. The stock has a market cap of $8.97 billion, a price-to-earnings ratio of 6.92, a P/E/G ratio of 0.37 and a beta of -0.48.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Tuesday, August 7th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.81 by $0.12. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. The company had revenue of $2.13 billion for the quarter, compared to analysts’ expectations of $2.05 billion. As a group, equities analysts anticipate that Bausch Health Companies will post 3.47 earnings per share for the current fiscal year.
In other news, CEO Joseph C. Papa acquired 30,000 shares of the firm’s stock in a transaction on Friday, September 14th. The stock was purchased at an average price of $22.32 per share, for a total transaction of $669,600.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Schutter Richard U. De acquired 125,000 shares of the firm’s stock in a transaction on Thursday, September 13th. The stock was purchased at an average price of $23.96 per share, with a total value of $2,995,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 165,000 shares of company stock worth $3,890,700 in the last 90 days. 11.54% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. Point View Wealth Management Inc. purchased a new stake in Bausch Health Companies in the 2nd quarter valued at about $1,132,000. Marshall Wace LLP purchased a new stake in Bausch Health Companies in the 2nd quarter valued at about $2,974,000. Van ECK Associates Corp purchased a new stake in Bausch Health Companies in the 2nd quarter valued at about $11,494,000. Tobam purchased a new stake in Bausch Health Companies in the 2nd quarter valued at about $13,886,000. Finally, Private Management Group Inc. purchased a new stake in Bausch Health Companies in the 2nd quarter valued at about $28,474,000. Hedge funds and other institutional investors own 43.16% of the company’s stock.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Further Reading: Do Tariffs Work?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.